Neural network learns to select potential anticancer drugs

Neural network learns to select potential anticancer drugs
AAE architecture. Credit: MIPT

Scientists from Mail.Ru group Insilico Medicine and MIPT have for the first time applied a generative neural network to create new pharmaceutical medicines with the desired characteristics. Generative adversarial networks (GANs) developed and trained to "invent" new molecular structures may produce a dramatic reduction in the time and cost of searching for substances with potential medicinal properties. The researchers intend to use these technologies in the search for new medications within various areas from oncology to CVDs and even anti-infectives. The first results were submitted to Oncotarget in June 2016. Since that time, the group has made many improvements to the system and engaged with some of the leading pharmaceutical companies.

Currently, the inorganic molecule base contains hundreds of millions of substances, and only a small fraction of them are used in medicinal drugs. The pharmacological methods of making drugs generally have a hereditary nature. For example, pharmacologists might continue to research aspirin that has already been in use for many years, perhaps adding something into the compound to reduce side effects or increase efficiency, yet the substance still remains the same. Earlier this year, the scientists at Insilico Medicine demonstrated that it is possible to substantially narrow the search using . But now they have focused on a much more challenging question: Is there a chance to create conceptually new molecules with medicinal properties using the novel flavor of deep neural networks trained on millions of ?

Generative adversarial autoencoder (AAE) architecture, an extension of generative adversarial networks, was used as the basis, and compounds with known medicinal properties and efficient concentrations were used to train the system. The researchers entered information on these types of compounds into the network. The system was then adjusted so that the same data was acquired in the output. The network itself was made up of three structural elements: an encoder, decoder and discriminator, each of which had its own specific role in cooperating with the other two. The encoder worked with the decoder to compress and then restore information on the parent compound, while the discriminator helped make the compressed presentation more suitable for subsequent recovery. Once the network learned a wide swath of known molecules, the encoder and discriminator "switched off," and the network generated descriptions of the molecules on its own using the decoder.

Developing generative adversarial networks that produce high-quality images based on text inputs requires substantial expertise and lengthy training time on high-performance computing equipment. But with images and videos, humans can quickly perform quality control of the output. In biology, quality control cannot be performed by the human eye, and a considerable number of validation experiments are required to produce viable molecules.

Neural network learns to select potential anticancer drugs
Drug selection. Credit: MIPT

But SMILEs do not do the job very well either, as they have a random length from one symbol to 200. Neural network training requires an equal description length for the vector. The "fingerprint" of a molecule suits this task, as it contains complete information on the molecule. There are a lot of methods for making these fingerprints, but the researchers used a simple binary one consisting of 166 digits. They converted SMILEs into fingerprints and taught the network with them, after which they entered fingerprints of known medicinal compounds into the network. The network's job was to allocate inner neuron parameter weights so that the specified input created the specified output. This operation was then repeated many times, as this is how training with large quantities of data is performed. As a result, a "black box" capable of producing a specified output for the specified input was created, after which the developers removed the first layers, and the network generated the fingerprints by itself when the information was run through again. The scientists thus built "fingerprints" for all 72 million molecules, and then compared the network-generated fingerprints with the base. The molecules were selected based on the specified qualities.

Andrei Kazennov, one of the authors of the study and an MIPT postgraduate who works at Insilico Medicine, comments, "We've created a neuronal network of the reproductive type, i.e., capable of producing objects similar to what it was trained on. We ultimately taught this network model to create new fingerprints based on specified properties."

The anticancer drug database was used to check the network. First, the was trained on one half of the medicinal compounds, and then checked on the other half. The purpose was to predict the compounds already known but not included in the training set. A total of 69 predicted compounds have been identified, and hundreds of molecules developed using a more powerful extension of the method are on the way.

According to one of the authors of the research, Alex Zhavoronkov, the founder of Insilico Medicine and international adjunct professor at MIPT, "Unlike the many other popular methods in deep learning, generative adversarial networks (GANs) were proposed only recently, in 2014, by Ian Goodfellow and Yoshua Bengio's group and scientists are still exploring its power in generating meaningful images, videos, works of art and even music. The pace of progress is accelerating and soon we are likely to see tremendous advances stemming from combinations of GANs with other methods. But everything that my groups are working on relates to extending human longevity, durability and increasing performance. When humans go to Mars, they will need the tools to be more resilient to all kinds of stress and be able to generate targeted medicine on demand. We will be the ones supplying these tools."

"GANs are very much the frontline of neuroscience. It is quite clear that they can be used for a much broader variety of tasks than the simple generation of images and music. We tried out this approach with bioinformatics and obtained great results," concludes Artur Kadurin, Mail.Ru Group lead programmer of the search optimizing team and Insilico Medicine independent science advisor.

More information: Artur Kadurin et al, The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology, Oncotarget (2016). DOI: 10.18632/oncotarget.14073

Journal information: Oncotarget
Citation: Neural network learns to select potential anticancer drugs (2017, February 10) retrieved 2 March 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Deep learning applied to drug discovery and repurposing


Feedback to editors